Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Camptothecin
  • Colorectal Neoplasms
  • Cost-Benefit Analysis
  • Genetic Testing
  • Glucuronosyltransferase

abstract

  • The current results indicated that pharmacogenetic testing for UGT1A1*28 variant homozygosity may be cost effective, but only if irinotecan dose reduction in homozygotes does not reduce efficacy. Future studies to evaluate reduced-dose efficacy in homozygotes should be considered.

publication date

  • September 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2853177

Digital Object Identifier (DOI)

  • 10.1002/cncr.24428

PubMed ID

  • 19517472

Additional Document Info

start page

  • 3858

end page

  • 67

volume

  • 115

number

  • 17